Merck Stock Edges Higher Despite Cautionary Targets

Merck & Co.'s stock price has been trading around $143 on the New York Stock Exchange as of mid-September 2026, still below the estimated fair value and price targets that range from $150 to above. Analysts remain cautiously optimistic about the company's prospects.

According to Morningstar, one widely followed narrative values Merck at approximately $150.42 per share, implying an undervaluation of around 4% compared to its recent closing price of roughly $143.79.

RBC Capital analyst Trung Huynh maintains a Hold rating on Merck & Company with a price target of $150.00 per share, several dollars above the current trading level and reflecting moderate upside but not an aggressive bull stance.

Merck's growth expectations depend heavily on its oncology portfolio and broader pipeline, particularly its leading cancer immunotherapy, Keytruda. The company has expanded the reach of clinical trials for this treatment, supporting expectations for continued revenue growth in oncology.